Selected Publications

Click on any article title below to view/download a PDF reprint

 

2017


Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity

Sabatino JJ Jr, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 4:e366. doi: 10.1212/ NXI.0000000000000366 (2017)


Induction of paralysis and visual system injury in mice by T cells specific for neuromyelitis optica autoantigen aquaporin-4

Sagan SA, Cruz-Herranz A, Spencer CM, Ho PP, Steinman L, Green AJ, Sobel RA, Zamvil SS. J Vis Exp (2017) (in press)


Acute liver injury in a Glatopa-treated patient with MS

Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC.  Neurol Neuroimmunol Neuroinflamm 4:e368 doi: 10.1212/ NXI.0000000000000368 (2017)


T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury

Cruz-Herranz A, Sagan SA, Sobel RA, Green AJ, Zamvil SS. J Nat Sci 3:e358 (2017)


 

2016


Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4.

Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, Levin MH, Verkman AS, Steinman L, Green AJ, Anderson MS, Sobel RA, Zamvil SS. Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1617859114 (2016)


B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue

Lehmann-Horn K, Wang SZ, Sagan SA, Zamvil SS, von Büdingen HC. JCI Insight 1:e87234 (2016)


Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.

Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CCA, Sobel RA, Cree BAC, Schulze-Topphoff U, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 3:e272. doi: 10.?1212/?NXI.?0000000000000272 (2016)


Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery.

Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, Lorrain DS, Pekarek K, A Sagan S, Xiao L, Teuscher C, von Büdingen HC, Wess J, Lawrence JJ, Green AJ, Fancy SP, Zamvil SS, Chan JR. Elife 5. pii: e18246. doi: 10.7554/eLife.18246 (2016)


Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls.

Tremlett H, Fadrosh DW, Faruqi AA, Hart J, Roalstad S, Graves J, Spencer CM, Lynch SV, Zamvil SS, Waubant E; US Network of Pediatric MS Centers. BMC Neurol 16:182 (2016)


Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens.

Cree BA, Spencer CM, Varrin-Doyer M, Baranzini SE, Zamvil SS. Ann Neurol 80:443–447. doi: 10.1002/ana.24718 (2016)


Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.

Steinman L, Zamvil SS. Curr Opin Neurol 29:340-4. doi: 10.1097/WCO.0000000000000317 (2016)


Antibodies in multiple sclerosis oligoclonal bands target debris.

Winger RC, Zamvil SS. Proc Natl Acad Sci U S A 113:7696-8. doi: 10.1073/pnas.1609246113 (2016)


Your nose knows how to target brain inflammation.

Winger RC, Zamvil SS. Brain 139:1866-9. doi: 10.1093/brain/aww121 (2016)


Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, Cree BA, Sobel RA, Wipke BT, Steinman L, Scannevin RH, Zamvil SS. Proc Natl Acad Sci U S A 11:4777-82. doi: 10.1073/pnas.1603907113 (2016)


CNS accumulation of regulatory B cells is VLA-4-dependent.

Lehmann-Horn K, Sagan SA, Winger RC, Spencer CM, Bernard CC, Sobel RA, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 3:e212. doi: 10.1212/NXI.0000000000000212 (2016)


 

2015


Glatiramer acetate treatment negatively regulates type I interferon signaling.

Molnarfi N, Prod'homme T, Schulze-Topphoff U, Spencer CM, Weber MS, Patarroyo JC, Lalive PH, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 2:e179. doi: 10.1212/NXI.0000000000000179 (2015)


Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation.

Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, Vagena E, Bedard C, Machado MR, Rios Coronado PE, Prod'homme T, Charo IF, Lassmann H, Degen JL, Zamvil SS, Akassoglou K. Nat Commun 6:8164. doi: 10.1038/ncomms9164 (2015)


The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis.

Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil SS, Ma A. Nat Immunol 16:618-27. doi: 10.1038/ni.3172 (2015)


B cell VLA-4-deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.

Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil SS. Ann Neurol 77:902–908. doi: 10.1002/ana.24387 (2015)


Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. 

Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BAC, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 2:e76; doi: 10.1212/NXI.0000000000000076 (2015)


Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? 

Zamvil SS, Slavin AJ. Neurol Neuroimmunol Neuroinflamm 2:e62. doi: 10.1212/NXI.0000000000000062 (2015)


 

2014


MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS

Varrin-Doyer M, Shetty A, Spencer CM, Schulze Topphoff U, Bernard CCA, Forsthuber T, Cree BAC, Slavin AJ, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 1:e20; doi: 10.1212/NXI.0000000000000020 (2014)


Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE. 

Shetty A, Gupta SG, Varrin-Doyer M, Weber MS, Prod'homme T, Molnarfi N, Ji N, Nelson PA, Patarroyo JC, Schulze-Topphoff U, Fogal SE, Forsthuber T, Sobel RA, Bernard CCA, Slavin AJ, Zamvil SS. Neurol Neuroimmunol Neuroinflamm 1:e22; doi: 10.1212/NXI.0000000000000022 (2014)


Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. 

Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. Exp Neurol pii: S0014-4886(14)00097-1. doi: 10.1016/j.expneurol.2014.04.002 (2014)


Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. 

Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. J Neuroinflammation 11:29 (2014)


 

2013


MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. 

Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS. J Exp Med 210:2921-37 (2013)


Therapeutic Decisions in Multiple Sclerosis: Moving Beyond Efficacy. 

Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. JAMA Neurol  doi: 10.1001/jamaneurol.2013.3510 (2013)


Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. 

Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Michel K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil SS, Baranzini SE. J Exp Med 210:1301-09 (2013)


 

2012


Aquaporin-4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter

Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BAC, Zamvil SS. Ann Neurol 72:53-64 (2012)


Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. 

Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, Sobel RA, Nelson PA, Zamvil SS. PLoS One 7:e33797 (2012)


Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. 

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team. Neurology 78:1171-8 (2012)


 

2011


B cells in multiple sclerosis: connecting the dots. 

Von Büdingen HC, Bar-Or A, Zamvil SS. Curr Opin Immunol 23:713-20 (2011)


Combining statins with interferon-beta in multiple sclerosis: think twice, it might not be all right. 

Zamvil SS, Steinman L. Lancet Neurol 10:672-3 (2011)


 

2010


Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. 

Nelson PA, Khodadoust M, Prodhomme T, Spencer C, Patarroyo JC, Varrin-Doyer M, Ho JD, Stroud RM, Zamvil SS. PLoS One 5:e15050 (2010)


B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS. Ann Neurol 68:369-83 (2010)


 

2008


Bench to Bedside: Tempering antigen-presenting cells in multiple sclerosis. 

Prod'homme T, Zamvil SS. Nat Med 14:614-615 (2008)


 

2007


Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. 

Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS. Nat Med 13:935-943 (2007)


T effectors outfox T regulators in autoimmunity. 

Prod'homme T, Weber MS, Zamvil SS. Nat Med 13:411-413 (2007)


 

2006


Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. 

Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS. J Clin Invest 116:1037-1044 (2006)


Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. 

Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. J Exp Med 203:401-412 (2006)


How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. 

Zamvil SS, Steinman L. Ann Neurol 60:12-21 (2006)


Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. 

Greenwood J, Steinman L, Zamvil SS. Nat Rev Immunol 6:358-370 (2006)


A neuropeptide in immune-mediated inflammation, Y? 

Prod'homme T, Weber MS, Steinman L, Zamvil SS. Trends Immunol 27:164-178 (2006)


 

2005


Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. 

Steinman L, Zamvil SS. Trends Immunol 26:565-571 (2005)


 

2003


Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. 

Zamvil SS, Steinman L. Neuron 38:685-688 (2003)


Transcriptional analysis of targets in multiple sclerosis. 

Zamvil SS, Steinman L. Nat Rev Immunol 3:483-492 (2003)


 

2002


The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. 

Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. Nature 420:78-84 (2002)


The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. 

Stuve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. J Immunol 169:6720-6732 (2002)


Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA). 

Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS. Genes and Immunity 3:34-37 (2002)


 

2001


Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. 

Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, Fontana A, Bikoff EK, Zamvil SS.  J Clin Invest 108:1133-1139 (2001)


Click here for a complete PubMed listing of Dr. Zamvil's publications